Annual report
4552.TEDINET S100QZ4J
Period2022-04-01 → 2023-03-31
Filed2023-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100SNAG (2024-01-19).
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥34.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥30.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥23.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥19.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥20.5bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.1bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.4bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥3.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥14.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥94.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥97.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥73.8bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥47.8bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥42.5bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥42.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥46.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥52.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥51.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥38.6bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥32.6bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥30.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.3bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.7bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥5.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥15.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥240m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥917m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥30.35 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥117.26 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.81 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.72 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥30.22 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.8 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥55.53 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.59 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥412.11 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥406.57 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥306.31 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥257.92 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥245.54 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 54.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.3% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.6% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 32.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 879 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 816 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 732 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 667 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 632 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥34.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥51.1bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥30.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥24.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.9bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥20.1bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥5.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥20.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.6bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥19.3bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥3.7bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥14.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥7.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.8bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥94.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥97.0bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥73.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥47.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥42.1bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥42.5bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥46.1bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥52.0bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥50.9bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥38.5bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥32.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥30.5bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥11.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥29.8bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥29.67 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.77 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥57.33 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.23 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.08 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥29.54 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.31 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥57.05 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.1 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.9 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25.5 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥410.86 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥407.02 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥307.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥257.01 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥244.24 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 54.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.8% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.5% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.3% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 32.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.3% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 129,686,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 129,686,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 129,686,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,421,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,421,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 854 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 797 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 719 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 654 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 613 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 879 pure |
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 854 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,443
| Item | Context | Value | Unit |
|---|---|---|---|
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember | 958000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | -63000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember | -0 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | -64000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember | 173000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember | 1067000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_TreasuryStockMember | -2978000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember | 50709000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | 555000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember | － | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | 555000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember | 740000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 52006000000 | JPY |
| Salaries and allowances sga | Prior1YearDuration_NonConsolidatedMember | 2672000000 | JPY |
| Salaries and allowances sga | CurrentYearDuration_NonConsolidatedMember | 2772000000 | JPY |
| Provision for bonuses sga | Prior1YearDuration_NonConsolidatedMember | 482000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration_NonConsolidatedMember | 411000000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration_NonConsolidatedMember | 102000000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration_NonConsolidatedMember | 114000000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration_NonConsolidatedMember | 84000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration_NonConsolidatedMember | 88000000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 92000000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 100000000 | JPY |
| Commission fee sga | Prior1YearDuration_NonConsolidatedMember | 5470000000 | JPY |
| Commission fee sga | CurrentYearDuration_NonConsolidatedMember | 3392000000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 7373000000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 8922000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-06-21 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第48期（自 2022年４月１日 至 2023年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ＪＣＲファーマ株式会社 | |
| Company name in english cover page | FilingDateInstant | JCR Pharmaceuticals Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役会長兼社長 芦田 信 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)兵庫県芦屋市春日町３番19号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)芦屋 0797(32）1995 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)上席執行役員経営戦略本部長 伊藤 洋 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)兵庫県芦屋市春日町３番19号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)芦屋 0797(32）1995 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)上席執行役員経営戦略本部長 伊藤 洋 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00973 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45520 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ＪＣＲファーマ株式会社 | |
| Filer name in english | FilingDateInstant | JCR Pharmaceuticals Co.,Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |